Scientists from the University of Washington and the Fred Hutchinson Cancer Research Center and their collaborators have described the generation of self-assembling nanoparticles displaying the Epstein-Barr virus (EBV) gH/gL glycoprotein complex as potential EBV vaccines.
Many pathogens such as HIV, SARS-CoV-2, or those linked to influenza or cholera infect the host through mucosal surfaces and thus are thought to require both systemic and mucosal immune responses for effective management and protection.
An effective universal vaccine ideally providing broad protection against all influenza A virus (IAV) subtypes with pandemic or zoonotic potential circulating in animals, as well as against antigenically variable seasonal strains, remains an urgent public health need.
After an eight-year odyssey, the first cytidine triphosphate synthase 1 (CTPS1) inhibitor has entered the clinic, with Step Pharma SAS announcing it has simultaneously begun studies in the U.S. and the U.K. The phase I/II trial is assessing Step’s lead program, STP-938, in relapsed/refractory B- and T-cell lymphomas, with the first U.S. site opening for enrollment this week.
Qu Biologics has received clearance from Health Canada to proceed with a randomized, placebo-controlled trial of QBKPN, a first-in-class innate immune modulator that enhances lung immunity, in the elderly.
RSS
